Akebia Therapeutics, Inc.

Thank you. Thank you for standing by. My name is Andrea and I will be your conference operator today. At this time, I would like to welcome everyone to the Akibia Second Quarter 2024 Financial Results. All lines have been placed in mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one in your telephone keypad. If you would like to draw your question, press star one again. I would now like to turn the call over to Mercedes Carrasco, Senior Director in Vistor Relations. Thank you. Please go ahead.

Thank you and welcome to Akibia's Second Quarter 2024 Financial Results and Business Updates Conference Call. Please note that a press release was issued earlier today, Thursday, August 8th, detailing our first quarter financial, second quarter financial results and that release is available on the investor section of our website. For your convenience, a replay of today's call will be available on our website after we conclude. Joining me for today's call, we have John Butler, Chief Executive Officer, Nick Gruns, Chief Commercial Officer, and Eric Ostrosky, Chief Financial and Business Officer. I'd like to remind everyone that this call includes forward-looking statements. Each forward-looking statement on this call is subject to risks and uncertainties that could cause actual results to differ materially from those described in these statements. Additional information describing these risks is included in the financial results press release that we issued on August 8th, as well in the risk, factors, and management discussion and analysis section of our most recent annual and quarterly reports filed with the SEC. With that, I'd like to introduce CEO John Butler.

John Butler Thanks, Mercedes, and thanks everyone for joining us today. Since the Vassio FDA approval in late March, virtually the entire company has been diligently focused on its commercial launch. Now, Nick's going to walk you through the details shortly, but the punchline is that in the four weeks since we spoke to you last, we've made significant progress on our key launch initiatives, which are first, driving prescriber demand, second, contracting effectively with dialysis organizations, and third, advancing plans to generate clinical data that could demonstrate potential additional benefits of Vassio. As recently announced, we filed our Tdapa application in June and are now about five months away from making Vassio available in the market. Our entire organization is incredibly energized by this upcoming event. We're encouraged by the strong reception for Vassio from the medical community. The excitement around Vassio was evident in two physician advisory boards we recently hosted. What's especially interesting is that these are physicians we haven't worked with in the past and are new to the Vassio story. The overwhelming response was that they're ready for a new choice in anemia management for dialysis patients. Our medical affairs team has been supporting dialysis organizations as they work to put Vassio clinical protocols in place ahead of Tdapa. Today, we have a full complement of MSLs who are actively engaged in physician education, armed with a wealth of clinical data, including the Vatadustat Phase 3 New England Journal publications, as well as the additional data we've generated to support healthcare providers' understanding and utilization of the product. Similarly, our commercial team has also been making good progress. Our field sales team is connecting with prescribers to drive awareness and demand. As we expand these discussions, physicians are very consistent in where they expect to use the product initially. The focus is on home patients as well as patients on the highest doses of ESAs. These are the segments where physicians attribute the greatest unmet need and they total more than 200,000 patients. We believe prescribers will expand utilization of Vassio beyond these patient groups after gaining experience with the product and seeing the benefits of Vassio for these initial patients. We're also very focused on the longer-term growth for Vassio. Generating new data to potentially expand the benefits of the product is critical. A key component of our strategy is to continue to generate this clinical data in collaboration with dialysis organizations. We're deeply engaged with DOs in study design and believe these studies may meaningfully contribute to continued growth of Vassio post-TDAPA in the dialysis population. We need to continue to generate important clinical data for Vassio to continue to move towards our goal of becoming a new standard of care. Think of it this way. Today we're targeting the Tdapa patient population with a premium price. Once Tdapa ends in 2027, we'll have a price consistent with the ESAs but we'll target the entire dialysis market, over 500,000 patients and approximately $1 billion today. New data along with the positive experience over the Tdapa period will be central to meeting our goal. The market for Vassio and dialysis is significant but let's also talk about potential expansion. Circling back to physician interest in Vassio, an unsurprising additional point continues to come up both in the advisory boards I mentioned earlier and in virtually every conversation we have with prescribers. Physicians see a clear and obvious unmet need in the treatment of anemia in CKD patients not on dialysis. We agree. Accordingly, we've prioritized Vassio label expansion for non-dialysis CKD patients. As we've said previously, we expect to provide a more detailed update on this initiative by the end of the year. Now let me turn it over to Nick to talk about our commercial progress.

Thanks, John, and thanks for those joining us on the call today. Our Vassio launch activities continue to ramp and evolve and we are making significant progress across all of our key initiatives targeting both the high-level patient makers as well as the doctors who are directly involved in patient care. The feedback we are getting on Vassio has been positive and doctors are enthusiastic about using the drug to help their dialysis patients, especially in patients who receive in-home dialysis, patients on high dose of the UCAs, or patients not achieving appropriate hemoglobin levels. We're also making strong advances on the contracting front where we are discussing our entire product portfolio which strengthens our dialogue with dialysis organizations. We have had contract conversations with dialysis organizations covering nearly 90 percent of patient lives with many more to come. In the next several months, I can tell you that dialysis organizations are looking for partners, partners who can help maximize the opportunity to incorporate innovative medications into their centers made possible by Tadapa and also navigate the changes that are necessary considering the high likelihood that phosphate binders will be added to the bundle. Akivia has been and will be that partner. Our national accounts team has been busy and every day the pace is accelerating. We have also heard uniformly about the high degree of change associated with binders in the bundle. This change in reimbursement dynamics for phosphate binders could be associated with a change in distribution channels and as a result in the traditional inventory purchasing patterns for this category, including Eriksia. As such, dialysis organizations are reviewing their supply chain logistics to optimize their economics both ahead of and during the Tadapa period. We are in the process of evaluating many new supply partners to minimize any disruption. That said, the change in distribution channel is not expected to impact overall demand for phosphate binders or Eriksia market share and we therefore anticipate similar revenue trends in 2024 as compared to last year, though the supply chain could see some fluctuation as these changes roll out. We have leveraged Eriksia contracting discussion to simultaneously engage in VATSIO contracting. There is significant value to us companies to have a portfolio of products promoted in the same space and it allows for meaningful operational and potential financial benefits to be realized. The VATSIO wholesale acquisition cost of approximately $15,500 per patient per year has been well received by our customers and stakeholders operating in the Tadapa environment who want to use VATSIO. We expect our product supply contracts with dialysis organizations will include an off invoice discount and a volume-based rebate. We also continue to work towards having all contracts complete by January. Before I turn it back to John, I wanted to quickly note progress from our international partner Medici. VATSIO is now available in Germany and Austria and Medici just recently launched in the Netherlands. It is still early days for the European launch but we are encouraged by our partners enthusiasm and execution in their launch. John?

Thanks Nick and now I'd like to introduce you to Eric Ostrowski who joined the Kibia in June as our chief financial officer and chief business officer. Eric has an impressive track record in corporate finance and financial team leadership. His skill set is highly complementary to our executive leadership team and he's already adding value to the business. Eric over to you to talk about our financial position.

Thanks John. I'm extremely pleased to have joined the Kibia and firmly believe this is a transformational time for the company. Now a month into the job my conviction is strengthened. With the VATSIO product launch and established revenue generating business in Erixia and a promising HISS-based pipeline, I believe a Kibia is well positioned for growth. And as importantly, I am happy to be working with a dedicated and hard-working team with such strong knowledge of and relationships in the renal space. Now let's review the quarterly finances. Total revenue was $43.6 million in the second quarter of 2024. Of this amount, $41.2 million was derived from Erixia net product revenue as compared to $42.2 million of Erixia net product revenue during the second quarter of 2023. The remainder of our revenues during the quarter were derived from license, collaboration and other revenues which totaled $2.4 million as compared to $14.1 million in the second quarter of 2023. Of note, last year's second quarter licensing collaboration revenues included a one-time $10 million upfront payment related to our Medici license agreement. Cost of goods sold was $17 million in the second quarter of 2024 compared to $17.3 million in the second quarter of 2023. Kibia continues to carry a non-cash intangible amortization charge of $9 million per quarter in COGS through the fourth quarter of 2024. Research and development expenses were $7.6 million in the second quarter of 2024 compared to $20.2 million in the second quarter of 2023. This decrease was driven by the completion of certain clinical trial activities, a reduction in consulting expenses and lower headcount related costs. Selling general and administrative expenses were $26.9 million in the second quarter of 2024 compared to $27 million in the second quarter of 2023. And lastly, net loss was $8.6 million in the second quarter of 2024 compared to a net loss of $11.2 million in the second quarter of 2023. Cash and cash equivalence is a June 30, 2024, worth $39.5 million and I'm pleased to say we expect to have at least two years of cash runway. Our cash position continues to be supported by revenue from Eriksia and careful expense management.

With that, we welcome questions.

Thank you. We will

now begin the question and answer session. If you have dialed in and would like to ask a question, please press star one in your telephone keypad to raise your hand and join the queue. If you would like to withdraw your question, simply press star one again. If you are called upon to ask a question and are listening via loudspeaker on your device, please pick up your handset and ensure that your phone is not in between asking a question. Again, press star one to join the queue. And your first question comes from the line of Julian Harrison with BTIG. Thank you. Please go ahead.

Thank you for taking my question and congrats on all the progress. Sorry if I missed it, but just want to confirm that it's still your expectation that you don't need to build out your sales force beyond what you already have for Eriksia and you probably don't need to manufacture additional API to meet initial demand for your VAPSEA launch expected January next year.

So Nick, do you want to talk about the sales force?

Absolutely. And so Julian, thanks for the question. Yeah, we've had a team in place for the entire year that's already been calling on dialysis organizations and providers. While there may be some small tweaking around the edges, I don't think there's going to be anything that I would regard as significant or material in how we approach the marketplace from a account perspective.

I think the bigger change that we had was adding to the medical affairs group. We had skinned down that group because medical affairs wasn't as impactful on Eriksia, but they're incredibly important for protocol development for the dialysis providers. So we did expand that group. As I said, it's fully staffed now and they're out there being very effective with physicians. And then your second question was API. And that's correct. We have product in place. Eric, maybe you want to kind of talk to that?

Yeah, we do. We have product in place. As has been discussed on prior calls, we do have some, will be effectively

zero cost inventory because it was previously expensive to R&D. So yeah, just to reiterate, we're well positioned from an inventory perspective for the launch.

Yeah, our quality team did a great job of generating data to expand the dating for the product. So everything we have on the shelf that we had for two years ago for the launch we were expecting, we can use now. And it's a great place to be just from the perspective that you don't have significant cash outlay for manufacturing. But of course, you do like to manufacture some product and keep your CDMOs current on the process. But it is helpful from

a cash perspective.

Okay, great. Thank you. And then one more, if I may. It's great to hear that you're already engaging dialysis providers representing, I think you said 90% of the addressable market already. I'm wondering how much of that you expect to be enabled through your recently updated relationship with CSLV4?

Yeah, no, it's a great question. It's frankly, we were already engaging with them around Erixia. If you remember, some of the catalysts for Erixia was the proposed rule that came out around binders in the bundle that helped dialysis organizations really understand that it was coming, which was a catalyst for their urgency to meet with us earlier in the year. And really the 90% is since the V4 announcement, we've met with providers representing 90%, approximately 90% of the patients. So the V4 catalyst becomes additional reasons for them to want to get us back in the room in order to discuss contracting and the process. Nick talked about

us becoming a partner. I think we've considered ourselves a partner for some time. But when you have to contract directly with the dialysis providers, and now we're doing that on two products, and particularly with phosphate binders, where there's going to be a lot of work for them to incorporate those into the, as you said, they're now purchasing the phosphate binder, managing that with their patients, a lot of work in that. And they really want to work with companies as closely as possible on a lot of operational aspects, not just contractual aspects. And that's where it's one of those reasons why it's so powerful to have both products that we're talking to them about. It just increases the partnership between Akibia and dialysis providers on some really core areas of their business.

The only thing I'll probably add to that is, you know, our history in dialysis allows those conversations to be one with a knowledge of their operational concerns, right? If you don't, if you walk into these conversations without the knowledge of how they think about their business and what's important to them, it does become a conversation that can appear very one-sided and out for Akibia only. And in a partnership, if they don't have an opportunity to be able to use the product successfully, then it's really not a partnership. And so creating that environment is really important.

Yeah.

And we've been saying for years how important knowing the dialysis business is. And I think Eric here for a month is learning how different and complicated dialysis can be. And that is a real competitive advantage for

us. Thanks for the questions, Julian.

Thank you. And your next question comes from the line of Ed Arcee with

HC Wynwright. Thank you. Please go ahead.

Hi. Good morning. Thanks for taking my questions and congrats on the progress towards the launch next year. A couple questions for me. First on the WAC price that you announced. Wondering if you could give a little details around some of the criteria as you thought through working to optimize the price not only for Tadapa but afterwards. And what sort of key aspects came into that thought process? Secondly, with Medici, wondering if you can disclose what proportion of the collaborative sales this quarter came from Germany. I think it was Germany and Australia which launched in June if there were any. And if there's any other further countries that you expect to come online between now and the end of the year. Thanks so much.

So I'll, Eric, do you want to just handle a second?

Yeah. I mean, that's a quick one. Yeah. So no revenues from Medici in this quarter. As you pointed out, that was, you know, a June launch.

Yeah. They just started. So, you know, we look forward to seeing that progress. I don't know if we have, Nick, do you know any other countries you're expecting to? I know there's other ones just went.

I know there's others

for

some of the other countries will be in the balance of the year.

Yeah. I mean, you know, the larger countries is where they have to do the price negotiation, which, you know, I think we'll start to see them come online next year. But the smaller countries like Netherlands and now the Nordic countries will come on sooner. Nick, you want to walk through the thoughts around WAC pricing?

Yeah. And so really WAC pricing, a couple different things is when we thought about it is one, what price would allow for dialysis organizations to be successful during the TADAPA period? And so how do you set up your contract? What is the WAC price? Is your reimbursement for the first several quarters of TADAPA and allowing TADAPA, which really supports innovative products being utilized, that WAC price and then how do we make it a price that makes our dialysis organizations and a key be a successful was a consideration. Two, how do we make sure we manage that price over the TADAPA period so that post TADAPA when we talk about ESA like pricing, we can manage ESA like pricing to make the product sustainable post TADAPA. Remember, it's a billion dollar market today at ESA pricing and therefore creating that predictability post TADAPA that the dialysis organizations wanted is critically important. And then lastly, but importantly, the non-dialysis population, less than 25% of patients today in the non-dialysis space are on an anemia management product or being treated for their anemia. And when they enter into dialysis, the outcomes associated with folks that have been treated versus those not is enormous. And so the value of having a product like Vassio in the non-dialysis space is very, very high and therefore are making sure we're pricing for that dynamic and that innovative value in that subset of population is important as well.

Yeah, I that last point is, you just can't be emphasized enough. And frankly, I mean, I think it really was a challenge balancing what's right for the dialysis market today versus, you know, what's possible and the benefit we would bring to the non-dialysis patient population. And I hope we struck the balance here. And, you know, particularly as Nick pointed out, that WAC reimbursement for the first few quarters of TADAPA is critical because there's some real costs for the dialysis providers to add a new product to the protocols in place, storage, et cetera. And, you know, they have to see the business rationale for them to do that. Yet, you also want to be very cognizant of the optics around, you know, kind of how pricing is viewed. So, you know, it's quite the balance we had to strike. We did a lot of and had a lot of conversations with folks before making that decision. And, you know, as Nick pointed out in his remarks, I think we did hit the right balance for the dialysis population. Folks are reacting quite well and are very willing to contract and put the product as part of their formula.

The only additional context I'll add is I've been with a lot of customers over the last month. And as you go through the WAC price and how to understand that, how to operationalize it, what it means in the context of the contract structure that we've talked about, an off invoice discount and volume-based rebates, which we've talked about again as volume goes up, their price goes down, which means their economics improve. They've looked at it and said, huh, that makes a lot of sense. Right? And that's what you really want from your customers is that that makes a lot of sense, that reinforcement that you've done the right thing for them, which is important.

And it really creates an environment where physicians can try BAPSC. Right? I mean, you know, as he said, you can have a great contract in place, but if you don't have physician demand, you know, they're not going to force that. Our sales force is driving that demand. And we know that if physicians have access and are able to use it, which we create through the contract, that physicians will like using the product. They'll see the benefits of using the product and they'll expand their use of the product. And that's what positions as well, even though post Tdapa, we're going to have to take this price cut, if you will. You know, we're now going to be targeting the entire dialysis market and people will be open to that. And that's a billion dollar market today. So that's a significant opportunity. And then hopefully, as possible thereafter, we introduce the product into the non dialysis market with a label in non dialysis. And then you'll start to have patients starting dialysis on BAPSC. So this is how you become standard of care. It's a process. First step in dialysis is you've got to have that contract in place that allows physicians to access the product. And that WAC pricing decision was very, very central to that, to making that possible.

Very helpful. Thanks so much. Thanks, Ed.

Thank you. There are no questions. I will now turn the conference back over to John Butler,

CEO for closing remarks.

Thanks, Andrea. We remain extremely energized by our contracting process and the upcoming VASIO market availability, which is not only a few months away. We're on target with all of our internal timelines and believe we will have all the pieces in place for a successful launch. I really look forward to seeing many of you at the Fall Investor Conferences and hopefully at the ASN Kidney Week

in October. Thanks, everyone. Enjoy the rest of your summer.

Thank you, ladies and gentlemen. That concludes today's call. Thank you all for

joining. You are now disconnect.

Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank

you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you for standing by. My name is Andrea and I will be your

conference operator today. At this time, I would like to welcome everyone to the KBS Second Quarter 2024 financial results. All lines have been placed in mute to prevent any background noise. After the speakers remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one in your telephone keypad. If you would like to withdraw your question, press star one again. I would now like to turn the call over to Mercedes Carrasco, senior director in this relation. Thank you. Please go ahead.

Thank you and welcome to KBS Second Quarter 2024 financial results and business updates conference call. Please note that a press release was issued earlier today, Thursday, August 8th, detailing our first quarter financial, second quarter financial results and that release is available on the investor section of our website. For your convenience, a replay of today's call will be available on our website after we conclude. Joining me for today's call, we have John Butler, chief executive officer, Nick Gruns, chief commercial officer, and Eric Ostrosky, chief financial and business officer. I would like to remind everyone that this call includes forward-looking statements. Each forward-looking statement on this call is subject to risks and uncertainties that could cause actual results to differ materially from those described in these statements. Additional information describing these risks is included in the financial results press release that we issued on August 8th, as well in the risk factors and management discussion and analysis section of our most recent annual and quarterly reports filed with the SEC. With that, I'd like to introduce CEO John Butler.

Thanks Mercedes and thanks everyone for joining us today. Since the Vassio FDA approval in late March, virtually the entire company has been diligently focused on its commercial launch. Now Nick's going to walk you through the details shortly, but the punchline is that in the four weeks since we spoke to you last, we've made significant progress on our key launch initiatives, which are first, driving prescriber demand, second, contracting effectively with dialysis organizations, and third, advancing plans to generate clinical data that could demonstrate potential additional benefits of Vassio. As recently announced, we filed our Tdapa application in June and are now about five months away from making Vassio available in the market. Our entire organization is incredibly energized by this upcoming event. We're encouraged by the strong reception for Vassio from the medical community. The excitement around Vassio was evident in two physician advisory boards we recently hosted. What's especially interesting is that these are physicians we haven't worked with in the past and are new to the Vassio story. The overwhelming response was that they're ready for a new choice in anemia management for dialysis patients. Our medical affairs team has been supporting dialysis organizations as they work to put Vassio clinical protocols in place ahead of Tdapa. Today, we have a full complement of MSLs who are actively engaged in physician education armed with a wealth of clinical data, including the VATADUSTAT Phase 3 New England Journal publications, as well as the additional data we've generated to support health care providers' understanding and utilization of the product. Similarly, our commercial team has also been making good progress. Our field sales team is connecting with prescribers to drive awareness and demand. As we expand these discussions, physicians are very consistent in where they expect to use the product initially. The focus is on home patients as well as patients on the highest doses of ESAs. These are the segments where physicians attribute the greatest unmet need and they total more than 200,000 patients. We believe prescribers will expand utilization of Vassio beyond these patient groups after gaining experience with the product and seeing the benefits of Vassio for these initial patients. We're also very focused on the longer-term growth for Vassio. Generating new data to potentially expand the benefits of the product is critical. A key component of our strategy is to continue to generate this clinical data in collaboration with dialysis organizations. We're deeply engaged with DOs in study design and believe these studies may meaningfully contribute to continued growth of Vassio post-TDAPA in the dialysis population. We need to continue to generate important clinical data for Vassio to continue to move towards our goal of becoming a new standard of care. Think of it this way. Today, we're targeting the Tdapa patient population with a premium price. Once Tdapa ends in 2027, we'll have a price consistent with MSAs, but we'll target the entire dialysis market, over 500,000 patients, and approximately $1 billion today. New data, along with the positive experience over the Tdapa period, will be central to meeting our goal. The market for Vassio and dialysis is significant, but let's also talk about potential expansion. Circling back to physician interest in Vassio, an unsurprising additional point continues to come up, both in the advisory boards I mentioned earlier and in virtually every conversation we have with prescribers. Physicians see a clear and obvious unmet need in the treatment of anemia in CKD patients not on dialysis. We agree. Accordingly, we've prioritized Vassio label expansion for non-dialysis CKD patients. As we've said previously, we expect to provide a more detailed update on this initiative by the end of the year. Now, let me turn it over to Nick to talk about our commercial progress.

Thanks, John, and thanks for those joining us on the call today. Our Vassio launch activities continue to ramp and evolve, and we are making significant progress across all of our key initiatives targeting both the high-level patient makers as well as the doctors who are directly involved in patient care. The feedback we are getting on Vassio has been positive, and doctors are enthusiastic about using the drug to help their dialysis patients, especially in patients who receive in-home dialysis, patients on high dose of the UCAs, or patients not achieving appropriate hemoglobin levels. We're also making strong advances on the contracting front, where we are discussing our entire product portfolio, which strengthens our dialogue with dialysis organizations. We have had contract conversations with dialysis organizations covering nearly 90 percent of patient lives, with many more to come. In the next several months, I can tell you that dialysis organizations are looking for partners, partners who can help maximize the opportunity to incorporate innovative medications into their centers made possible by Tadapa and also navigate the changes that are necessary considering the high likelihood that phosphate binders will be added to the bundle. Akivia has been and will be that partner. Our national accounts team has been busy, and every day the pace is accelerating. We have also heard uniformly about the high degree of change associated with binders in the bundle. This change in reimbursement dynamics for phosphate binders could be associated with a change in distribution channels, and as a result, in the traditional inventory purchasing patterns for this category, including Eriksia. As such, dialysis organizations are reviewing their supply chain logistics to optimize their economics, both ahead of and during the Tadapa period. We are in the process of evaluating many new supply partners to minimize any disruption. That said, the change in distribution channel is not expected to impact overall demand for phosphate binders or Eriksia market share, and we therefore anticipate similar revenue trends in 2024 as compared to last year, though the supply chain could see some fluctuation as these changes roll out. We have leveraged Eriksia contracting to simultaneously engage in Vatio contracting. There is significant value to us as a company to have a portfolio of products promoted in the same space, and it allows for meaningful operational and potential financial benefits to be realized. The Vatio wholesale acquisition costs of approximately $15,500 per patient per year has been well received by our customers and stakeholders operating in the Tadapa environment who want to use Vatio. We expect our product supply contracts with dialysis organizations will include an off-invoice discount and a volume-based rebate. We also continue to work towards having all contracts complete by January. Before I turn it back to John, I wanted to quickly note progress from our international partner, Medici. Vatio is now available in Germany and Austria, and Medici just recently launched in the Netherlands. It is still early days for the European launch, but we are encouraged by our

support. Thanks, Nick. Now I would like to introduce you to Eric Ostrowski, who joined the Kibia in June as our Chief Financial Officer and Chief Business Officer. Eric has an impressive track record in corporate finance and financial team leadership. His skill set is highly complementary to our executive leadership team, and he is already adding value to the business. Eric, over to you to talk about our financial position.

Thanks, John. I am extremely pleased to have joined the Kibia and firmly believe this is a transformational time for the company. Now a month into the job, my conviction is strengthened. With the Vatio product launch and established revenue-generating business in Eriksia and a promising hits-based pipeline, I believe the Kibia is well positioned for growth. And as importantly, I am happy to be working with a dedicated and hardworking team with such strong knowledge of and relationships in the renal space. Now let's review the quarterly financial. Total revenue was $43.6 million in the second quarter of 2024. Of this amount, $41.2 million was derived from Eriksia net product revenue as compared to $42.2 million of Eriksia net product revenue during the second quarter of 2023. The remainder of our revenues during the quarter were derived from license, collaboration, and other revenues, which total $2.4 million as compared to $14.1 million in the second quarter of 2023. Of note, last year's second quarter licensing collaboration revenues included a one-time $10 million upfront payment related to our Medici license agreement. Cost of goods sold was $17 million in the second quarter of 2024 compared to $17.3 million in the second quarter 2023. Kibia continues to carry a non-cash and tangible amortization charge of $9 million per quarter in COGS through the fourth quarter of 2024. Research and development expenses were $7.6 million in the second quarter of 2024 compared to $20.2 million in the second quarter of 2023. This decrease was driven by the completion of certain clinical trial activities, a reduction in consulting expenses, and lower headcount related costs. Selling general and administrative expenses were $26.9 million in the second quarter of 2024 compared to $27 million in the second quarter of 2023. And lastly, net loss was $8.6 million in the second quarter of 2024 compared to a net loss of $11.2 million in the second quarter of 2023. Cash and cash equivalence is a June 30, 2024, or $39.5 million. And I'm pleased to say we expect to have at least two years of cash runway. Our cash position continues to be supported by revenue from Eriksia and careful expense management.

And with that, we welcome questions.

Thank

you. We will now begin the question and

answer session. If you have dialed in and would like to ask a question, please press star one in telephone keypad to raise your hand and join the queue. If you would like to withdraw your question, simply press star one again. If you are called upon to ask a question and are listening by a loudspeaker on your device, please pick up your handset and ensure that your phone is not in mute when asking a question. Again, press star one to join the queue. And your first question comes from the line of Julian Harrison with BTIG. Thank you. Please go ahead.

Thank you for taking my question and congrats on all the progress. Sorry if I missed it, but just want to confirm that it's still your expectation that you don't need to build out your Salesforce beyond what you already have for Eriksia and you probably don't need to manufacture additional API to meet initial demand for your VAPSEA launch expected January next year.

So

Nick, do you want to talk about Salesforce?

Absolutely. And so Julian, thanks for the question. Yeah, we've had a team in place for the entire year that's already been calling on dialysis organizations and providers. While there may be some small tweaking around the edges, I don't think there's going to be anything that I would regard as significant or material in how we approach the marketplace from a account perspective.

I think the bigger change that we had was adding the medical affairs group. We had skinny down that group because medical affairs wasn't as impactful on Eriksia, but they're incredibly important for protocol development for the dialysis providers. So we did expand that group. As I said, it's fully staffed now and they're out there being very effective with physicians. And then your second question was around API and that's correct. We have product in place. Eric, maybe you want to talk to that?

Yeah, we do. We have product in place. This has been discussed on prior calls. We do have some, it will be effectively zero

cost inventory because it was previously expensive to R&D. So yeah, just to reiterate, we're well positioned from an inventory perspective for the launch.

Our quality team did a great job of generating data to expand the dating for the product. So everything we have on the shelf that we had for two years ago for the launch we were expecting, we can use now. And it's a great place to be just from the perspective that you don't have significant cash outlay for manufacturing. But of course, you do like to some product and keep your CDMOs current on the

process.

But

it is helpful from a cash perspective.

Okay, great. Thank you. And then one more, if I may. It's great to hear that you're already engaging dialysis providers representing, I think you said 90% of the addressable market already. I'm wondering how much of that you expect to be enabled through your recently updated relationship with CSLV for?

Yeah, no, it's a great question. It's frankly, we were already engaging with them around Erixia. If you remember, some of the catalysts for Erixia was the proposed rule that came out around binders in the bundle that helped dialysis organizations really understand that it was coming, which was a catalyst for their urgency to meet with us earlier in the year. And really the 90% is since the V4 announcement, we've met with providers representing 90%, approximately 90% of the patients. So the V4 catalyst becomes additional reasons for them to want to get us back in the room in order to discuss contracting and the process. Nick talked

about us becoming a partner. I think we've considered ourselves a partner for some time. But when you have to contract directly with the dialysis providers, and now we're doing that on two products, and particularly with phosphate binders, where there's going to be a lot of work for them to incorporate those into the, as you said, they're now purchasing the phosphate binder, managing that with their patients, a lot of work in that. And they really want to work with companies as closely as possible on a lot of operational aspects, not just contractual aspects. And that's where it's one of those reasons why it's so powerful to have both products that we're talking to them about. It just increases the partnership between Akibia and dialysis providers on some really core areas

of

their business.

The only thing I'll probably add to that is our history in dialysis allows those conversations to be one with a knowledge of their operational concerns. If you walk into these conversations without the knowledge of how they think about their business and what's important to them, it does become a conversation that can appear very one-sided and out for Akibia only. And in a partnership, if they don't have an opportunity to be able to use the product successfully, then it's really not a partnership. And so creating that environment is really

important.

We've

been saying for years how important knowing the dialysis business is. And I think Eric here for a month is learning how different and complicated dialysis can be. And that is a real competitive advantage for

us. Thanks for the questions, Julian.

Thank you. And your next question comes from the line of Ed Arcee with

HC Wynright. Thank you. Please go ahead.

Hi. Good morning. Thanks for taking my questions and congrats on the progress towards the launch next year. A couple of questions for me first on the WAC price that you announced. I'm wondering if you could give a little details around some of the criteria as you thought through working to optimize the price not only for Tadapa but afterwards. And what sort of key aspects came into that thought process? Secondly, with Medici, I'm wondering if you can disclose what proportion of the collaborative sales this quarter came from Germany. I think it was Germany and Australia which launched in June if there were any. And if there's any other further countries that you expect to come online between now and the end of the year. Thanks so much.

So Eric, do you want to just handle a second one?

Yeah, that's a quick one. So no revenues from Medici in this quarter. As you pointed out, that was a June launch.

Yeah, they just started. So we look forward to seeing that progress. I don't know if we have, do you know any other countries you're expecting to? I know there's other ones just went. There

are

others for

some of the other Nordic countries that will be in the balance of the year.

Yeah, I mean, the larger countries is where they have to do the price negotiation which I think we'll start to see them come online next year. But the smaller countries like Netherlands and now the Nordic countries will come on sooner. Nick, you want to walk through the thoughts around whack pricing? Yeah,

and so really, whack pricing, a couple different things is when we thought about it is one, what price would allow for dialysis organizations to be successful during the Tadapa period? And so how do you set up your contract? What is the whack price? Is your reimbursement for the first several quarters of Tadapa and allowing Tadapa, which really supports innovative products being utilized, that whack price and then how do we make it a price that makes our dialysis organizations and Aqibia successful was a consideration. Two, how do we make sure we manage that price over the Tadapa period so that post-Tadapa when we talk about ESA-like pricing, we can manage ESA-like pricing to make the product sustainable post-Tadapa. Remember, it's a billion dollar market today at ESA pricing and therefore creating that predictability post-Tadapa that the dialysis organizations wanted is critically important. And then lastly, but importantly, the non-dialysis population. Less than 25% of patients today in the non-dialysis space are on an anemia management product or being treated for their anemia. And when they enter into dialysis, the outcomes associated with folks that have been treated versus those not is enormous. And so the value of having a product like Vassio in the non-dialysis space is very, very high and therefore are making sure we're pricing for that dynamic and that innovative value in that subset of population is important as well.

Yeah, that last point is, just can't be emphasized enough. And frankly, I mean, I think it really was a challenge balancing what's right for the dialysis market today versus what's possible and the benefit we would bring to the non-dialysis patient population. I hope we've struck the balance here. Particularly as Nick pointed out, that WAC reimbursement for the first few quarters of Tdapa is critical because there's some real operational costs for the dialysis providers to add a new product to put protocols in place, storage, et cetera. And they have to see the business rationale for them to do that. Yet, you also want to be very cognizant of the optics around kind of how pricing is viewed. So it's quite the balance we had to strike. We did a lot of and had a lot of conversations with folks before making that decision. And as Nick pointed out in his remarks, I think we did hit the right balance for the dialysis population. Folks are reacting quite well and are very willing to contract and put the product as part of their formula. The

only additional context I'll add is I've been with a lot of customers over the last month. And as you go through the WAC price and how to understand that, how to operationalize it, what it means in the context of the contract structure that we've talked about, an off invoice discount and volume-based rebates, which we've talked about again as volume goes up, their price goes down, which means their economics improve. They've looked at it and said, huh, that makes a lot of sense. And that's what you really want from your customers is that that makes a lot of sense, that reinforcement that you've done the right thing for them, which is important.

And it it really creates an environment where physicians can try BAPSC. As he said, you can have a great contract in place, but if you don't have physician demand, they're not going to force that. Our sales force is driving that demand. And we know that if physicians have access and are able to use it, which we create through the contracting, that physicians will like using the product, they'll see the benefits of using the product, and they'll expand their use of the product. And that's what positions as well, even though post-TDAPA, we're going to have to take this price cut, if you will, we're now going to be targeting the entire dialysis market and people will be open to that. And that's a billion dollar market today. So that's a significant opportunity. And then hopefully, as shortly as possible thereafter, we introduce the product into the non-dialysis market with a label in non-dialysis. And then you'll start to have patients starting dialysis on BAPSC. So this is how you become standard of care. It's a process. First step in dialysis is you've got to have that contract in place that allows physicians to access the product. And that WAC pricing decision was very, very central to that, to making that possible.

Very helpful. Thanks so much. Thanks, Ed.

Thank you. There are no questions. I will now turn the conference back over to John Butler,

CEO for closing remarks.

Thanks, Andrea. We remain extremely energized by our contracting process and the upcoming VASIO market availability, which is not only a few months away. We're on target with all of our internal timelines and believe we will have all the pieces in place for a successful launch. I really look forward to seeing many of you at the Fall Investor Conferences and hopefully at the ASN Kidney Week

in October. Thanks, everyone. Enjoy the rest of your summer.

Thank you, ladies and gentlemen. That concludes today's call. Thank you all for joining Human Health Disconnect.